NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 66-71, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.6671

Nanotechnology-Based Targeting of Adipose Tissue Inflammation in Obesity: Mechanisms, Challenges, and Therapeutic Opportunities

Serunjogi Ruth

Department of Clinical Pharmacy Kampala International University Uganda
Email: ruth.serunjogi@studwc.kiu.ac.ug

ABSTRACT

Obesity is characterized by chronic low-grade inflammation within adipose tissue, which plays a central role in the development of insulin resistance, type 2 diabetes, cardiovascular disease, and other metabolic complications. Conventional anti-inflammatory and metabolic therapies often lack tissue specificity, leading to limited efficacy and systemic side effects. Nanotechnology has emerged as a powerful platform to overcome these limitations by enabling targeted delivery of therapeutic agents directly to inflamed adipose tissue. Nanocarriers can be engineered to exploit adipose tissue vascularization, immune cell infiltration, and molecular signatures associated with obesity-induced inflammation. This review provides a comprehensive overview of nanotechnology-based strategies for targeting adipose tissue inflammation in obesity. We discuss the underlying mechanisms of adipose tissue inflammation, design principles of nanocarriers, and current nanotherapeutic approaches, including drug-loaded nanoparticles, gene delivery systems, and biomimetic platforms. Key challenges such as biological barriers, safety, scalability, and regulatory considerations are critically examined. Finally, we highlight emerging therapeutic opportunities and future directions for translating nanotechnology-driven adipose tissue targeting into clinically viable obesity treatments.

Keywords: nanotechnology; obesity; adipose tissue; inflammation; targeted therapy

INTRODUCTION

Obesity has reached epidemic proportions globally, posing a major public health challenge due to its strong association with metabolic disorders such as type 2 diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, and certain cancers[1–3]. Beyond excessive fat accumulation, obesity is now recognized as a state of chronic, low-grade systemic inflammation, with adipose tissue acting as a central inflammatory organ[4, 5]. Adipose tissue inflammation is characterized by immune cell infiltration, dysregulated adipokine secretion, and activation of pro-inflammatory signaling pathways that collectively impair metabolic homeostasis[6, 7].

In lean individuals, adipose tissue functions as a dynamic endocrine organ that regulates energy balance through the secretion of adipokines such as adiponectin and leptin. However, during obesity, adipocyte hypertrophy, hypoxia, and cellular stress trigger the release of chemokines and danger-associated molecular patterns that recruit immune cells, particularly macrophages[8–10]. These macrophages undergo phenotypic switching from an anti-inflammatory M2 state to a pro-inflammatory M1 state, leading to increased production of tumor necrosis factor-α, interleukin-6, and other inflammatory mediators[11–14]. This inflammatory milieu interferes with insulin signaling pathways, promoting systemic insulin resistance.

Despite extensive research into obesity-related inflammation, current pharmacological interventions remain suboptimal. Systemic anti-inflammatory drugs lack specificity for adipose tissue and may suppress beneficial immune functions in other organs. Similarly, metabolic drugs often fail to adequately address the inflammatory component of obesity or require high doses that increase the risk of adverse effects[15, 15–17]. Therefore, there

is a critical need for therapeutic strategies that selectively target inflamed adipose tissue while minimizing off-target toxicity.

Nanotechnology offers unique advantages for addressing this challenge. Nanoparticles can be engineered with precise control over size, shape, surface chemistry, and cargo composition, enabling them to navigate biological barriers and preferentially accumulate in specific tissues. In the context of obesity, nanocarriers can exploit the enhanced vascular permeability, immune cell activity, and molecular markers present in inflamed adipose tissue[18–20]. Moreover, nanotechnology enables the co-delivery of multiple therapeutic agents, such as anti-inflammatory drugs and gene regulators, allowing for synergistic modulation of adipose tissue pathology.

Over the past decade, significant progress has been made in developing nanotechnology-based systems for targeting adipose tissue inflammation. These include polymeric nanoparticles, lipid-based carriers, inorganic nanoparticles, and biomimetic platforms designed to deliver small molecules, nucleic acids, or biologics[21]. Preclinical studies have demonstrated promising results in reducing adipose inflammation, improving insulin sensitivity, and mitigating metabolic dysfunction. However, translation to clinical practice remains limited due to challenges related to safety, scalability, and regulatory approval[22]. This review aims to provide a comprehensive analysis of nanotechnology-based targeting of adipose tissue inflammation in obesity. We first examine the mechanisms underlying adipose tissue inflammation and their relevance to nanotherapeutic targeting. We then discuss current nanocarrier designs and therapeutic strategies, followed by an evaluation of key challenges and limitations. Finally, we explore emerging opportunities and future perspectives for integrating nanotechnology into obesity management.

2. Mechanisms of Adipose Tissue Inflammation in Obesity

Adipose tissue inflammation in obesity arises from a complex interplay of cellular, molecular, and metabolic stressors. One of the earliest events is adipocyte hypertrophy, which occurs as energy intake chronically exceeds expenditure[4, 15, 17]. Enlarged adipocytes experience mechanical stress and impaired oxygen diffusion, leading to local hypoxia. Hypoxic conditions activate hypoxia-inducible factors that stimulate the expression of pro-inflammatory genes and angiogenic factors, altering the adipose tissue microenvironment[7, 23].

As adipocytes expand, they exhibit increased lipolysis and release excess free fatty acids into the extracellular space[24]. These lipids act as ligands for pattern recognition receptors such as Toll-like receptor 4 on immune cells, triggering inflammatory signaling cascades. In parallel, stressed or dying adipocytes release chemokines including monocyte chemoattractant protein-1, which recruits circulating monocytes into adipose tissue[10]. Once infiltrated, these monocytes differentiate into macrophages that cluster around necrotic adipocytes, forming crown-like structures that are hallmarks of inflamed adipose tissue[11–13].

Macrophage polarization plays a pivotal role in sustaining adipose inflammation. In lean adipose tissue, macrophages predominantly exhibit an M2 phenotype, supporting tissue remodeling and insulin sensitivity[22]. Obesity induces a shift toward the M1 phenotype, characterized by the secretion of pro-inflammatory cytokines and reactive oxygen species. This phenotypic switch amplifies local inflammation and disrupts insulin receptor signaling in adipocytes through serine phosphorylation of insulin receptor substrates[22].

Other immune cells, including T lymphocytes, B cells, neutrophils, and mast cells, also contribute to adipose tissue inflammation. Pro-inflammatory T helper 1 cells and cytotoxic CD8+ T cells increase in obese adipose tissue, while regulatory T cells decline. These changes further skew the immune balance toward inflammation[25]. Additionally, adipokine dysregulation, marked by decreased adiponectin and increased leptin and resistin, reinforces inflammatory signaling and metabolic dysfunction.

The chronic inflammatory state of adipose tissue has systemic consequences. Inflammatory mediators released into circulation affect liver, muscle, and pancreatic function, contributing to whole-body insulin resistance and metabolic disease progression[26, 27]. Understanding these mechanisms is essential for designing nanotechnology-based interventions that selectively target key inflammatory pathways and cellular populations within adipose tissue.

3. Nanotechnology Platforms for Targeting Adipose Tissue

Nanotechnology-based platforms provide versatile tools for delivering therapeutic agents to inflamed adipose tissue with high specificity. The design of nanocarriers typically considers size, surface charge, composition, and functionalization to optimize biodistribution and cellular uptake[18–20, 28]. Nanoparticles ranging from 50 to 200 nm are generally favored, as they can circulate for extended periods while extravasating into tissues with enhanced vascular permeability, such as inflamed adipose depots[29].

Polymeric nanoparticles are among the most widely explored systems for adipose tissue targeting. Biodegradable polymers such as poly(lactic-co-glycolic acid) allow controlled drug release and can be functionalized with targeting ligands[30]. Lipid-based nanoparticles, including liposomes and solid lipid nanoparticles, offer high biocompatibility and efficient encapsulation of hydrophobic drugs. These carriers can merge with cellular membranes, facilitating intracellular delivery of anti-inflammatory agents[30].

Inorganic nanoparticles, such as gold, silica, and iron oxide nanoparticles, provide unique physicochemical properties that enable imaging-guided therapy and stimulus-responsive drug release[30]. Magnetic nanoparticles, for example, can be directed to specific adipose depots using external magnetic fields, enhancing

local drug concentration. However, concerns regarding long-term accumulation and toxicity necessitate careful material selection and surface modification[31].

Surface functionalization plays a critical role in achieving adipose tissue specificity. Nanocarriers can be decorated with peptides, antibodies, or small molecules that recognize markers overexpressed in inflamed adipose tissue, such as vascular cell adhesion molecules or scavenger receptors on macrophages[32]. Alternatively, biomimetic strategies, including coating nanoparticles with cell membranes derived from macrophages or platelets, enable immune evasion and preferential homing to inflammatory sites[32]. Collectively, these nanotechnology platforms offer customizable and multifunctional approaches for targeting adipose tissue inflammation, laying the foundation for advanced therapeutic strategies in obesity.

4. Nanotechnology-Based Therapeutic Strategies

Nanotechnology enables a broad range of therapeutic strategies aimed at modulating adipose tissue inflammation. One major approach involves the delivery of conventional anti-inflammatory drugs directly to adipose tissue. Encapsulation of corticosteroids, non-steroidal anti-inflammatory drugs, or natural anti-inflammatory compounds within nanoparticles enhances their local efficacy while reducing systemic exposure and side effects. Gene-based therapies represent another promising strategy[18, 29, 33]. Nanocarriers can deliver small interfering RNA or microRNA mimics to silence pro-inflammatory genes or restore regulatory pathways in adipocytes and immune cells. For example, silencing genes involved in nuclear factor-κB signaling within adipose macrophages has been shown to reduce cytokine production and improve insulin sensitivity in preclinical models.

Nanoparticles can also be used to reprogram immune cell phenotypes within adipose tissue. Targeted delivery of immunomodulatory agents that promote macrophage polarization toward the M2 phenotype helps restore an anti-inflammatory environment. Similarly, nanoparticles delivering adiponectin or adiponectin-mimetic peptides can counteract adipokine imbalance and improve metabolic outcomes[34].

Combination therapies are increasingly explored, leveraging the ability of nanocarriers to co-encapsulate multiple agents. For instance, nanoparticles carrying both anti-inflammatory drugs and insulin-sensitizing agents can address multiple pathological processes simultaneously[35, 36]. Stimuli-responsive nanoparticles that release their cargo in response to pH, enzymes, or oxidative stress present in inflamed adipose tissue further enhance therapeutic precision[37].

These nanotechnology-based therapeutic strategies demonstrate significant potential for reshaping obesity treatment by directly targeting the inflammatory roots of metabolic dysfunction.

5. Biological and Technical Challenges

Despite encouraging preclinical results, several biological and technical challenges hinder the clinical translation of nanotechnology-based adipose tissue targeting[38]. One major obstacle is the complex biodistribution of nanoparticles following systemic administration. The reticuloendothelial system, particularly the liver and spleen, often sequesters nanoparticles, reducing their availability for adipose tissue targeting[38].

Heterogeneity among adipose depots also complicates targeting strategies. Visceral and subcutaneous adipose tissues differ in vascularization, immune cell composition, and inflammatory status, which may influence nanoparticle accumulation and therapeutic response[39]. Additionally, inter-individual variability in obesity severity and metabolic health further affects treatment outcomes.

Safety and toxicity concerns remain paramount. While many nanomaterials are designed to be biodegradable, their degradation products and long-term effects must be thoroughly evaluated. Immune reactions, unintended immunosuppression, and off-target gene modulation are potential risks associated with nanotherapeutics[40, 41].

From a technical standpoint, large-scale manufacturing, reproducibility, and stability of nanocarriers pose significant challenges. Regulatory frameworks for nanomedicines are still evolving, and stringent quality control standards are required to ensure consistency and safety[42, 43]. Addressing these challenges is essential for advancing nanotechnology-based therapies from bench to bedside.

6. Emerging Opportunities and Future Directions

Advances in materials science, bioengineering, and systems biology are opening new opportunities for nanotechnology-based targeting of adipose tissue inflammation. Personalized nanomedicine approaches that tailor nanocarrier design to individual inflammatory and metabolic profiles may enhance therapeutic efficacy[44]. Integration of diagnostic and therapeutic functions into theranostic nanoparticles enables real-time monitoring of treatment response[44, 45].

The use of biomimetic and bioinspired nanocarriers is gaining momentum. Cell membrane-coated nanoparticles and exosome-based delivery systems offer improved biocompatibility and targeting precision[46]. Additionally, leveraging artificial intelligence and machine learning to optimize nanoparticle design and predict biodistribution patterns holds promise for accelerating development.

Emerging delivery routes, such as localized injection into specific adipose depots or transdermal delivery systems, may further reduce systemic exposure and enhance targeting efficiency. Combining nanotechnology with lifestyle interventions and existing pharmacotherapies could provide synergistic benefits in obesity management[46].

Continued interdisciplinary collaboration among researchers, clinicians, and regulatory agencies will be critical for translating these emerging opportunities into safe and effective therapies.

CONCLUSION

Nanotechnology-based targeting of adipose tissue inflammation represents a transformative approach to obesity treatment. By enabling precise delivery of therapeutic agents to inflamed adipose depots, nanocarriers address key limitations of conventional systemic therapies. Advances in nanoparticle design, targeting strategies, and immunomodulation have demonstrated substantial potential to reduce inflammation and improve metabolic health in preclinical models. However, significant challenges related to biodistribution, safety, scalability, and regulatory approval remain. Overcoming these barriers will require rigorous evaluation, standardized manufacturing practices, and well-designed clinical trials. As our understanding of adipose tissue biology and nanomaterial interactions continues to evolve, nanotechnology-driven interventions are poised to play an increasingly important role in combating obesity and its associated metabolic diseases.

REFERENCES

1. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. Cancers. 12, 3798 (2020). https://doi.org/10.3390/cancers12123798
2. Bays, H.E., Kirkpatrick, C., Maki, K.C., Toth, P.P., Morgan, R.T., Tondt, J., Christensen, S.M., Dixon, D., Jacobson, T.A.: Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obes. Pillars. 10, 100108 (2024). https://doi.org/10.1016/j.obpill.2024.100108
3. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
4. Atangwho, I.J., Omang, W.A., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
5. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
6. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
7. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
8. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
9. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat. Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
10. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
11. Brancewicz, J., Wójcik, N., Sarnowska, Z., Robak, J., Król, M.: The Multifaceted Role of Macrophages in Biology and Diseases. Int. J. Mol. Sci. 26, 2107 (2025). https://doi.org/10.3390/ijms26052107
12. Guria, S., Hoory, A., Das, S., Chattopadhyay, D., Mukherjee, S.: Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci. Rep. 43, BSR20220200 (2023). https://doi.org/10.1042/BSR20220200
13. Nawaz, A., Fujisaka, S., Kado, T., Jeelani, I., Tobe, K.: Heterogeneity of adipose tissue-resident macrophages-beyond M1/M2 paradigm. Diabetol. Int. 14, 125–133 (2023). https://doi.org/10.1007/s13340-023-00624-2
14. Almohaimeed, H.M., Almars, A.I., Tounsi, W.A., Mohammedsaleh, Z.M., Panigrahi, R., Singh, I., Singh, S., Dhara, B., Uti, D.E.: Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases. J. Clin. Immunol. 46, 3 (2025). https://doi.org/10.1007/s10875-025-01965-0
15. Bera, R., Pathak, S., Srivastava, P., Ghosh, M., Sharma, A., Ahmed, N.Z., Karwasra, R., Akram, U., Kumar, P., Sharma, B., Sharma, N.: Biomimetic nanocarriers for the therapy and management of intestinal inflammations. Int. J. Pharm. X. 10, 100377 (2025). https://doi.org/10.1016/j.ijpx.2025.100377

16. Choi, H.M., Doss, H.M., Kim, K.S.: Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int. J. Mol. Sci. 21, 1219 (2020). https://doi.org/10.3390/ijms21041219
17. Divella, R., De Luca, R., Abbate, I., Naglieri, E., Daniele, A.: Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J. Cancer. 7, 2346–2359 (2016). https://doi.org/10.7150/jca.16884
18. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B.H., Anjum, I.: Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. Pharmaceuticals. 14, 707 (2021). https://doi.org/10.3390/ph14080707
19. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
20. Gholami, A., Mohkam, M., Soleimanian, S., Sadraeian, M., Lauto, A.: Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsyst. Nanoeng. 10, 1–43 (2024). https://doi.org/10.1038/s41378-024-00743-z
21. Singh, M.B., Raghav, S., Chavda, V., Singh, P., Yadav, S.K., Kim, W., Jain, P.: Advancing drug solubility and precision delivery with next-generation nanocarriers: Recent innovations, opportunities, and challenges. Nano Trends. 13, 100183 (2026). https://doi.org/10.1016/j.nwnano.2026.100183
22. Lin, X., Chen, L., Jia, K., Li, S., Li, Q., Yi, J., Xing, J.: Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases. Int. J. Nanomedicine. 21, 1–34 (2026). https://doi.org/10.2147/IJN.S566642
23. Aloh, H.E., Obasi, D.C., Okoroh, P.N., Aniokete, U.C., Emeruwa, A.P.: Maternal Nutrition and Toxicant Interactions as Epigenetic Architects | DMSO.
24. Zhang, Q., Lu, C., Lu, F., Liao, Y., Cai, J., Gao, J.: Challenges and opportunities in obesity: the role of adipocytes during tissue fibrosis. Front. Endocrinol. 15, (2024). https://doi.org/10.3389/fendo.2024.1365156
25. Lee, B.-C., Lee, J.: Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1842, 446–462 (2014). https://doi.org/10.1016/j.bbadis.2013.05.017
26. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
27. Elieh Ali Komi, D., Shafaghat, F., Christian, M.: Crosstalk Between Mast Cells and Adipocytes in Physiologic and Pathologic Conditions. Clin. Rev. Allergy Immunol. 58, 388–400 (2020). https://doi.org/10.1007/s12016-020-08785-7
28. Ghadami, A., Fathi-karkan, S., Siddiqui, B., Gondal, S.A., Rahdar, A., Garousi, N.A., Kharaba, Z., Ghotekar, S.: Nanotechnology in Imatinib delivery: advancing cancer treatment through innovative nanoparticles. Med. Oncol. 42, 116 (2025). https://doi.org/10.1007/s12032-025-02660-1
29. Krsek, A., Baticic, L.: Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer's and Parkinson's Disease. Future Pharmacol. 4, 352–379 (2024). https://doi.org/10.3390/futurepharmacol4020020
30. Shivanna, A.T., Dash, B.S., Lu, Y.-J., Lin, W.-T., Chen, J.-P.: Magnetic lipid-poly(lactic-co-glycolic acid) nanoparticles conjugated with epidermal growth factor receptor antibody for dual-targeted delivery of CPT-11. Int. J. Pharm. 667, 124856 (2024). https://doi.org/10.1016/j.ijpharm.2024.124856
31. Anselmo, A.C., Mitragotri, S.: A Review of Clinical Translation of Inorganic Nanoparticles. AAPS J. 17, 1041–1054 (2015). https://doi.org/10.1208/s12248-015-9780-2
32. Wang, L., Jia, Q., He, J., Li, Y.: Adipose tissue-targeting nanomedicines for obesity pharmacotherapy. Trends Endocrinol. Metab. 36, 1127–1139 (2025). https://doi.org/10.1016/j.tem.2025.03.010
33. Wang, S., Wang, Y., Chen, Q.: Nanotechnology-driven strategies for gene therapy of arthritis. Mater. Today Bio. 35, 102301 (2025). https://doi.org/10.1016/j.mtbio.2025.102301
34. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
35. Li, X., Peng, X., Zoulikha, M., Boafo, G.F., Magar, K.T., Ju, Y., He, W.: Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct. Target. Ther. 9, 1 (2024). https://doi.org/10.1038/s41392-023-01668-1
36. Guo, R., Zhang, Z., Zhang, S., Gai, T., Yu, H., Su, L., Yin, H., Wang, X., Zhang, Y.: Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery. Mater. Today Bio. 34, 102180 (2025). https://doi.org/10.1016/j.mtbio.2025.102180
37. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542

38. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
39. Lee, M.-J., Wu, Y., Fried, S.K.: Adipose Tissue Heterogeneity: Implication of depot differences in adipose tissue for Obesity Complications. Mol. Aspects Med. 34, 1–11 (2013). https://doi.org/10.1016/j.mam.2012.10.001
40. Onaciu, A., Jurj, A., Moldovan, C., Berindan-Neagoe, I., Onaciu, A., Jurj, A., Moldovan, C., Berindan-Neagoe, I.: Theranostic Nanoparticles and Their Spectrum in Cancer. In: Engineered Nanomaterials - Health and Safety. IntechOpen (2019)
41. Zao, X., Li, W., Cheng, L., Yu, B., Sa, G.: Physiological and Molecular Mechanisms of Light-Induced Greening in Potatoes: A Path to Food Safety. Foods. 14, 1798 (2025). https://doi.org/10.3390/foods14101798
42. Khan, S., Huda, B., Bhurka, F., Patnaik, R., Banerjee, Y.: Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms26178429
43. Li, G., Fang, X., Liu, Y., Lu, X., Liu, Y., Li, Y., Zhao, Z., Liu, B., Yang, R.: Lipid Regulatory Element Interact with CD44 on Mitochondrial Bioenergetics in Bovine Adipocyte Differentiation and Lipometabolism. J. Agric. Food Chem. 72, 17481–17498 (2024). https://doi.org/10.1021/acs.jafc.4c02434
44. Mohaghegh, N., Balajam, N.Z., Hosseinpour, B., Buttles, C., Huang, Q., Huang, Y., Ahari, A., Farhadi, N., Davani, S., Khosravi, S., Mirmashhouri, B., Kouchehbaghi, N.H., Sampath, R., Akbari, M., Jucaud, V., Kang, H., Khademhosseini, A., Pearson, R.M., Najafabadi, A.H.: Immunoengineering strategies using nanoparticles for obesity treatment. Nano Res. 18, 94907707 (2025). https://doi.org/10.26599/NR.2025.94907707
45. Omang, W.A., Bawa, I., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
46. Chennamsetty, S., Keerikkadu, M., Shetty, A., Bangera, P.D., Tippavajhala, V.K., Rathnanand, M.: Biohybrid nanocarriers for targeted drug delivery by integrating biological interfaces with synthetic platforms for site-specific therapeutics. Int. J. Pharm. 687, 126400 (2026). https://doi.org/10.1016/j.ijpharm.2025.126400

CITE AS: Serunjogi Ruth (2026). Nanotechnology-Based Targeting of Adipose Tissue Inflammation in Obesity: Mechanisms, Challenges, and Therapeutic Opportunities. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):66-71. https://doi.org/10.59298/NIJSES/2026/72.6671